Despite these findings, the current standard practice is to not recommend HSCT for NHB patients with NPM1 mutations in first remission and highlights the need to incorporate patient specific outcomes, such as the presence of MRD at the time of remission, known to be highly prognostic in NMP1-mutated AML [46,47]. The gene discussed is NPM1; the disease is acute myeloid leukemia.